Instrumento Inactivo

Otros idiomas Cytori Therapeutics Inc Nasdaq

Acciones

US23283K1051

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial	08/05
Plus Therapeutics : The use of CNSide in Clinical Management of LMD	08/05
Plus Therapeutics Announces Private Placement Financing of up to $18 Million	06/05
Plus Therapeutics, Inc. announced that it expects to receive $17.948504 million in funding from Aigh Capital Management, LLC	06/05
Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024	29/04
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	22/04
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense	22/04
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	22/04
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team	09/04
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference	27/03
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic	25/03
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	25/03
Plus Therapeutics : March 2024 Corporate Presentation	13/03
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases	11/03
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	11/03
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	05/03
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
North American Morning Briefing : S&P 500 Futures -2-	05/03
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024	27/02
Plus Updates Financial and Cash Guidance for 2024	18/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Cytori Therapeutics Inc Nasdaq

Acciones

US23283K1051

Otros idiomas

Filtros